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Abstract
Model-informed precision dosing (MIPD) using therapeutic drug/biomarker monitoring of-
fers the opportunity to significantly improve the efficacy and safety of drug therapies. Current
strategies comprise model-informed dosing tables or are based on maximum a-posteriori estimates.
These approaches, however, lack a quantification of uncertainty and/or consider only part of the
available patient-specific information. We propose three novel approaches for MIPD employing
Bayesian data assimilation (DA) and/or reinforcement learning (RL) to control neutropenia, the
major dose-limiting side effect in anticancer chemotherapy. These approaches have the potential
to substantially reduce the incidence of life-threatening grade 4 and subtherapeutic grade 0 neu-
tropenia compared to existing approaches. We further show that RL allows to gain further insights
by identifying patient factors that drive dose decisions. Due to its flexibility, the proposed com-
bined DA-RL approach can easily be extended to integrate multiple endpoints or patient-reported
outcomes, thereby promising important benefits for future personalized therapies.
1 INTRODUCTION
Personalized dosing offers the opportunity to improve safety and efficacy of drugs beyond the current
practice [1]. This is particularly crucial for drugs that exhibit narrow therapeutic indices relative to the
variability between patients. Patient-specific dose adaptations during ongoing treatments are, however,
difficult due to the need to integrate multiple sources of information, the lack of precise guidelines for
dose adaptations in the label and limited time resources [2, 3].
A particularly critical case is cytotoxic anticancer chemotherapy with neutropenia as major dose-
limiting toxicity [4]. Patients with severe neutropenia experience a drastic reduction of neutrophil
granulocytes and are thus highly susceptible to potentially life-threatening infections. Depending
on the lowest neutrophil concentration (nadir), the different grades g of neutropenia range from no
neutropenia (g = 0) to life-threatening (g = 4) [5]. At the same time, neutropenia serves as a
surrogate for efficacy (in terms of median survival) [6, 7, 8]. Neutrophil counts can therefore be used
as a biomarker to guide dosing [9, 10, 11].
In this article, we consider paclitaxel-induced neutropenia as an illustrative and therapeutically
relevant application. Paclitaxel is used as first-line treatment against non-small-cell lung cancer in
platinum-based combination therapy [12]. The standard dosing of paclitaxel is based on the patient’s
body surface area (BSA). To individualize treatment, a dosing table based on sex, age, BSA, drug
exposure and toxicity was developed [13] and evaluated in a clinical trial (hereafter “CEPAC-TDM
study”) [14].
Model-informed precision dosing (MIPD) describes approaches for dose individualization that take
into account prior knowledge on the drug-disease-patient system and associated variability, e.g., from a
nonlinear mixed effects (NLME) analysis as well as patient-specific therapeutic drug/biomarker mon-
itoring (TDM) data [15]. A popular approach is based on maximum a-posteriori (MAP) estimation
[16, 17, 18], which infers the individual model parameters of the pharmacokinetic/pharmacodynamic
(PK/PD) model. MAP-based outcomes are typically evaluated with respect to a utility function or
a target concentration to determine the next dose (MAP-guided dosing) [19, 17]. The definition of a
target concentration or utility function is, however, difficult since in many therapies rather subthera-
peutic or toxic ranges are known. For therapeutic ranges MAP-guided dosing is inaccurate [20], since
only a point estimate is used, neglecting associated uncertainties [21].
Recently, we have shown that Bayesian data assimilation (DA) approaches provide more informative
clinical decision support, fully exploiting patient-specific information [21]. DA allows for individualized
uncertainty quantification, which is a necessity (i) to integrate both, safety and efficacy aspects into the
objective function of finding the optimal dose, or (ii) to compute the probability of being within/outside
the target range. However, optimizing across a whole therapy time frame can be hard and potentially
too costly for real-time decision support.
Reinforcement learning (RL) has been applied to various fields in health care, however, mainly
focusing on clinical trial design [22, 23], and only few studies relate to optimal dosing in a PK/PD
context [24, 25]. In model-based RL, it is learned how to act best in an uncertain environment using
model simulations. A key aspect of learning is to make successively use of knowledge already acquired,
while also exploring yet unknown sequences of actions. The result is typically a decision tree (or some
functional relationship). In other words, the physician’s decision is supported via a pre-calculated,
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extensive and detailed look-up table without additional online computation. So far, RL approaches
in health care are limited to rather simple exploration strategies (so-called -greedy approaches) with
one time step ahead approximations of the look-up table (Q-learning) [23].
In this article, we demonstrate how DA and RL can be very beneficially exploited to develop new
approaches to MIPD. The first approach, referred to as DA-guided dosing, improves existing online
MIPD by integrating model uncertainties into the dose selection process. For the second approach
(RL-guided dosing) we propose Monte Carlo tree search (MCTS) in conjunction with the upper con-
fidence bound applied to trees (UCT) [26, 27] as sophisticated learning strategy. The third approach
combines DA and RL (DA-RL-guided) to make full use of patient TDM data and to provide a flexible,
interpretable and extendable framework. We compared the three proposed approaches with current
dosing strategies in terms of dosing performance and their ability to provide insights into the factors
driving dose selection.
2 METHODS
We consider a single dose every three weeks schedule for paclitaxel-based chemotherapy, usually termed
a cycle c = 1, . . . , C, for a total of six cycles (C = 6). We denote the decision time point for the dose of
cycle c by Tc, and assume T1 = 0 (therapy start). For dose selection, the physician has different sources
of information available, such as the patient’s covariates ‘cov’ (sex, age, etc), the treatment history
(drug, dosing regimen, etc), TDM data related to PK/PD (drug concentrations, response, toxicity,
etc). Despite these multiple sources of information, it remains a partial and imperfect information
problem, as only noisy measurements of few quantities of interest at certain time points are available.
MIPD aims to provide decision support by linking prior information on the drug-patient-disease system
with patient-specific TDM data.
The standard dosing for 3-weekly paclitaxel, as applied in the CEPAC-TDM study arm A, is
200 mg/m2 BSA and a 20 % dose reduction if neutropenia grade 4 (gc = 4) was observed [14]. The
aforementioned dosing table (termed PK-guided dosing [13]) was evaluated in study arm B, see Sec-
tion S 3. For dose selection at cycle start Tc, we chose the patient state
sc−1 =
(
sex, age; ANC0, g1, . . . , gc−1
)
, (1)
with s0 = (sex, age; ANC0). The covariates sex, age, have previously been identified as important
predictors of exposure [13], and baseline absolute neutrophil counts ANC0, as a crucial parameter in
the drug-effect model [28, 29]. We included the neutropenia grades of all previous cycles g1:c−1 =
(g1, . . . , gc−1) to account for the observed cumulative behavior of neutropenia [29, 30].
2.1 MIPD framework
MIPD builds on prior knowledge from NLME analyses of clinical studies [21]. The structural and
observational models are generally given as
dx
dt
(t) = f(x(t); θ, d), x(0) = x0(θ) (2)
h(t) = h(x(t), θ) (3)
with state vector x = x(t) (e.g., neutrophil concentration), parameter values θ (e.g., mean transition
time) and rates of change f(x; θ, d) for given doses d. The initial conditions x0 are given by the
pre-treatment levels (e.g., ANC0). A statistical model links the observables, the quantities that can
be measured hj(θ) = h(x(tj), θ) at time points tj to observations (tj , yj)j=1,...,n taking into account
measurement errors and potential model misspecifications, e.g.,
Yj|Θ=θ = hj(θ) + j (4)
with j ∼iid N (0,Σ). In more general terms, Yj|Θ=θ ∼ p
( · |θ;hj(θ),Σ) , with j = 1, . . . , n independent.
The prior distribution for the individual parameters is given by a covariate and statistical model,
Θ ∼ pΘ
(
θTV(cov),Ω
)
(5)
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with θTV(cov) denoting the typical values (TV), which generally depend on covariates ‘cov’, and Ω
the inter-individual variability . We used the term ‘model’ to refer to eqs. (2)-(5), and the term
‘model state of the patient’ to refer to a model-based representation of the state of the patient, i.e.,
a distribution of state-parameter pairs (x, θ), or just a single (reference) state-parameter pair. In the
proposed approaches, the model is used to simulate treatment outcomes (in RL called “simulated
experience”), or to assimilate TDM data and infer the model state of the patient, or both. To infer the
patient state (1), the grade of neutropenia of the previous cycle gc−1 needs to be determined; either
directly from the TDM data (yc−1 7→ gc−1 7→ sc−1) or based on a model simulation of the model state
of the patient ((x, θ) 7→ cnadir 7→ gc−1 7→ sc−1).
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1Figure 1: Overview of different approaches for model-informed precision dosing (MIPD).
The different methods can be categorized according to the time when the computational effort to
calculate the optimal dose must be made. Offline approaches calculate optimal doses for all possible
covariates and state combinations prior to any treatment, like in model-informed dosing tables (MIDT)
and reinforcement learning (RL). The physician selects the dosing recommendation in the table/tree
based on specific patient information (covariates, observations). While the TDM data (measured
biomarker) are used to determine the entry in the table/tree, the table/tree itself is static. Online
approaches solve an optimization problem at any decision time point, i.e., when a dose has to be
given. They integrate patient-specific TDM data using Bayesian data assimilation (DA) or maximum
a-posteriori (MAP) estimation. Offline–online approaches allocate computational resources between
offline and online. Pre-calculated dosing decision-trees are individualized during treatment, based on
TDM data.
We considered three different approaches towards MIPD, see Figure 1:
(i) Offline approaches support dose individualization based on model-informed dosing tables (MIDT)
or dosing decision trees (RL-guided dosing). At the start of therapy a dose based on the patient’s co-
variates and baseline measurements is recommended. During therapy, the observed TDM data are
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used to determine a path through the table/tree; While the treatment is individualized to the patient
(based on a-priori uncertainties), the procedure of dose individualization itself does not change, i.e.,
the tree/table is static. As such, it can be communicated to the physician before the start of therapy.
(ii) Online approaches determine dose recommendations based on a model state of the patient and
its simulated outcome. Bayesian DA or MAP estimation assimilate individual TDM data to infer the
posterior distribution or MAP point-estimate as model state of the patient, respectively. While online
approaches tailor the model (more precisely, the parameters) to the patient, clinical implementation
requires an IT infrastructure and expert personnel, which constitutes a current challenging problem
and hinders broad application [31].
(iii) Offline–Online approaches combine the advantages of dosing decision trees and an individu-
alised model. The individualised model is used in two ways, to infer the patient state more reliably
than sparsely observed TDM data and to individualize the dosing decision tree (using individualized
uncertainties, rather than population-based uncertainties).
Key to all approaches is the so-called reward function R (RL terminology), also termed cost or utility
function, defined on the set S of patient states
R : S → R. (6)
Ideally, the reward corresponds to the net utility of beneficial and noxious effects in a patient given the
current state [32]. For neutrophil-guided dosing, a reward function was suggested that maps (MAP-
based) nadir concentrations to a continuous score [19] or penalizes the deviation from a target nadir
concentration [17], see also Section S 8.5 and Figure S 8. The individualized uncertainties quantified via
DA allow to consider the probability of being within/outside the target range in the reward function
[21], which is more closely related to clinical reality. For the patient state (1) used in RL we also
designed the reward function to account for efficacy and toxicity. We chose to penalize the short-
term goal (avoiding life-threatening grade 4) more than the long-term goal (increased median survival
associated with neutropenia grades 1-4 [8]) :
R(sc) =

−1 if gc = 0 ,
1 if gc = 1, 2, 3 ,
−2 if gc = 4 .
(7)
2.2 RL-guided dosing
RL problems can be formalized as Markov decision processes, modeling sequential decision making
under uncertainty, and are closely related to stochastic optimal control [33]. In RL, the goal of a
so-called agent (here: the virtual physician) is to learn a policy (strategy) of how to act (dose) best
with respect to optimizing a specific expected long-term return (response), given an uncertain and
delayed feedback environment (virtual patient) [34, 35, 36, 37], see Figure 2.
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1Figure 2: Model-based reinforcement learning (planning). The expected long-term return
(action-value function) is estimated based on simulated experience (sample approximation Eq. (12)).
For simulating experience, an ensemble of virtual patients is generated, k = 1 . . . ,K (for all covariate
classes COV l, l = 1, . . . , L, covariates cov(k) are sampled within the covariate class and model param-
eters θ(k) are sampled from the prior distribution). At start of each cycle c, a dose d
(k)
c+1 is chosen
according to the current policy pik, and the outcome (grade of neutropenia) is predicted based on the
model x˙ = f(x; θ(k), d
(k)
c ) for the sample parameter vector θ(k) and chosen dose. The updated patient
state s
(k)
c is assessed using the reward function R. The sequential dose selections (going through the
circle C times (left part)) lead to so-called sample episodes; the entirety of episodes to a tree structure.
A Markov decision process comprises a sequence including states Sc, actions Dc and rewards Rc with
the subscript c referring to time (e.g., treatment cycle). If there is a natural notion of a final time c = C
(e.g., therapy of six cycles), the sequence is called an episode. Every episode corresponds to a path in the
tree of possibilities (Figure 2). Due to unexplained variability between patients (and occasions), transi-
tions between states are characterized by transition probabilities P[Sc+1 = sc+1|Sc = sc, Dc+1 = dc+1].
The reward is defined via the reward function, i.e., Rc = R(Sc), while a so-called dosing policy pi
models how to choose the next dose
pi(d|s) = P[Dc+1 = d|Sc = s]. (8)
A dosing policy is evaluated based on the so-called return Gc at time step c, defined as the weighted
sum of rewards over the remaining course of therapy
Gc = Rc+1 + γRc+2 + · · ·+ γC−(c+1)RC =
C∑
k=c+1
γk−(c+1)Rk . (9)
The discount factor γ ∈ [0, 1] balances between short-term (γ → 0) and long-term (γ → 1) therapeutic
goals (see Sections S 6 and S 8.7.1). Ultimately, the objective is to maximize the expected long-term
return
qpi(s, d) := Epi[Gc|Sc = s,Dc+1 = d] , (10)
given the current state Sc = s and dose Dc+1 = d over the space of dosing policies pi. The function
qpi is called the action-value function [35]. Due to the close interplay between qpi and pi, learning an
optimal policy involves an iterative process of value estimation and policy improvement [35].
Model-based RL methods that rely on sampling (sample-based planning) estimate the expected
value in eq. (10) via a sample approximation. To simplify the calculations we have discretized ‘age’
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and ANC0 into covariate classes COV l, l = 1, . . . , L. For each class COV l consider the ensemble
ERL(COV l) :=
{(
x0(θ
(k)
c ), θ
(k)
c , cov
(k)
)}K
k=1
with cov(k) sampled within COV l according to the covariate distributions in the CEPAC-TDM study
[14, 38], parameter values sampled from pΘ
(
θTV(cov(k)),Ω
)
and initial states according to (2). Then,
for each k = 1, . . . ,K with K large, a sample episode
s
(k)
0
d
(k)
1−→ (s(k)1 , r(k)1 )
d
(k)
2−→ (s(k)2 , r(k)2 )
d
(k)
3−→ . . . d
(k)
C−→ (s(k)C , r(k)C ) (11)
using policy pik is determined and
qk(s, d) =
1
Nk(s, d)
k∑
k′=1
nc∑
c=1
1
(s
(k′)
c =s,d
(k′)
c+1=d)
G(k
′)
c (12)
computed. Here, Nk(s, d) denotes the number of times that dose d was chosen in patient state s
amongst the first k episodes, and G
(k)
c = r
(k)
c+1 + γr
(k)
c+2 + . . .. Ideally, Nk(s, d) should be large for
each state-dose combination to guarantee a good approximation of the expected return (law of large
numbers). This, however, is infeasible for most applications (curse of dimensionality).
Therefore, we employed MCTS in conjunction with UCT as policy in the iterative training process
[39, 40, 26, 41, 27]:
pik+1(dc+1|sc) =
1 if dc+1 = arg maxd∈D UCTk(sc, d) ,0 else (13)
with UCTk defined based on the current sample estimate qk(sc, d)
UCTk(sc, d) = qk(sc, d)︸ ︷︷ ︸
exploitation
+c
√
Nk(sc)
Nk(sc, d) + 1︸ ︷︷ ︸
exploration
. (14)
It successively expands the search tree (Figure 2) by focusing on promising doses (exploitation, large
qk(sc, d)), while also encouraging exploration of doses that have not yet been tested exhaustively (small
Nk(sc, d) relative to the total number of visits Nk(sc) :=
∑
d′ Nk(sc, d
′) to state sc). The parameter
c balances exploration vs. exploitation; it depends on the range of possible values of the return and
current state of the therapy (cycle c), see eq. (S 10). Finally, we define piUCT = piK as estimate of the
optimal dosing policy in the training setting (learning with virtual patients), and qˆpiUCT = qK as an
estimate of the associated expected long term return. In a clinical TDM setting (RL-guided dosing),
we finally use pi∗ = arg max qˆpiUCT , i.e., c = 0 (no exploration) in Eq. (14). See Section S 6.1 for
details.
2.3 DA-guided dosing
Sequential DA approaches have been introduced as more informative and unbiased alternatives to
MAP-based predictions of the therapy outcome, since they more comprehensively make use of patient-
specific TDM data [21]. The individualized uncertainty in the model state of the patient is inferred
and propagated to the predicted therapy time course, allowing to predict the probability of possible
outcomes. For this, the uncertainty in the individual model parameters is sequentially updated via
Bayes’ formula, i.e.,
p(θ|y1:c) ∝ p(yc|θ) · p(θ|y1:c−1) , (15)
where y1:c = (y1, . . . , yc)
T denotes the TDM data up to and including cycle c, and yc = (yc1, . . . , ycnc)
T
the measurements taken in cycle c. Since the posterior distribution p(θ|y1:c) generally cannot be
determined analytically, DA approaches approximate it by an ensemble of so-called particles:
E1:c :=
{(
x
(m)
1:c , θ
(m)
c , w
(m)
c
)}M
m=1
.
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In our context, a particle represents a potential model state of the patient (for the specific patient
covariates cov) with a weighting factor w
(m)
c characterizing how probable the state is (given prior
knowledge and TDM data up to c). As more TDM data is gathered, the Bayesian updates reduce the
uncertainty in the model parameters and consequently in the therapeutic outcome, see Figure 3 (DA
part, reduced width of CrI/PI) and Section S 5. Since subtherapeutic as well as toxic ranges, i.e., very
low or high drug/biomarker concentrations, are described by the tails of the posterior distribution, the
uncertainties provide crucial additional information compared to the mode (MAP estimate) for dose
selection.
We chose the optimal dose to be the dose that minimizes the weighted risk of being outside the
target range, i.e., the a-posteriori probability of gc = 0 or gc = 4:
d∗c+1 = arg min
d∈D
λ0
M∑
m=1
w(m)c 1{g(θ(m)c ,d)=0} + λ4
M∑
m=1
w(m)c 1{g(θ(m)c ,d)=4} (16)
with g(θ
(m)
c , d) denoting the predicted neutropenia grade by forward simulation of the m-th particle
for dose d. We penalized grade 4 more severely than grade 0, i.e., λ4 = 2/3 and λ0 = 1/3, similarly as
in (7).
The integration of an ensemble of particles into the optimization problem, instead of a point esti-
mate (as in MAP-guided dosing), increases the computational effort and complexity of the problem. If
time or computing power is limited, approximations have to be used, e.g., by solving only for the next
cycle dose rather than all remaining cycles at the cost of neglecting long-term effects. Alternatively,
the number of particles M could be reduced (we used both approximations in this study); see also
Section S 8.6. The DA optimization problem is stated in the space of actions (doses), while RL opti-
mizes in the space of states by estimating the expected long-term return as intermediate step (eq. 12)
thereby promising efficient solutions to the sequential decision-making problem under uncertainty [35].
2.4 DA-RL-guided dosing
The particle-based DA scheme and the model-based RL scheme address the problem of personalized
dosing from different angles. A combined DA-RL approach therefore offers several advantages by
integrating individualized uncertainties provided by DA within RL, see Figure 3. First, instead of the
observed grade (e.g., measured neutrophil concentration on a given day, translated into the neutropenia
grade), we may use the smoothed posterior expectation of the quantity of interest (e.g., predicted nadir
concentration), see Section S 7. This reduces the impact of measurement noise and the dependence
on the sampling day. Second, for model simulations within the RL scheme, we can sample from the
posterior p(θ|y1:c) represented by the ensemble E1:c, i.e., from individualized uncertainties, instead of
the prior p(θ), i.e. population-based uncertainties. During the course of the treatment, the ensemble
of potential model states of the patient is continuously updated when new patient-specific data are
obtained (see eq. (15)). This allows to individualize the expected long-term return during treatment
as new patient data is observed, see Figure 3, i.e., the dosing decision tree in RL is updated prior to
the next dosing decision.
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1Figure 3: The interplay of data assimilation (DA) and reinforcement learning (RL). In the
planning phase prior to therapy, the expected long-term return qpi0 := qˆpiUCT is estimated in Monte
Carlo Tree search (MCTS) with upper confidence bound applied to trees (UCT) using an ensemble of
covariates cov(k) and parameter values θ(k) ∼ p(·|θTV(cov(k)),Ω). The first dose is selected based on
qpi0 := qˆpiUCT for the patient specific covariate class. The DA algorithm initializes a particle ensemble
given the patient’s covariates cov. The ensemble is propagated forward continuously in time, and
observed patient TDM data (black crosses) is assimilated when it becomes available. This results in
updated uncertainty, visible as ’cuts’ in the credible/prediction intervals. In contrast, the RL state
evolves in discrete time steps c according to the decision time points and only considers selected
features/summaries of the model state of the patient, e.g., smoothed posterior expectation of nadir
concentrations translated into neutropenia grades. At each decision time point, the posterior model
state of the patient is used to refine the prior computed qˆpiUCT (grey tree) for future reachable states
(light purple tree). This individualizes the tree based on individualized uncertainties (E1:c).
Since the refinement as well as the DA part has to run in real time (online), it has to be performed
efficiently. We do not need to take all possible state combinations into account, but only those that
are still relevant for the remaining part of the therapy. This reduces the computational effort, in
particular for later cycles. The proposed DA-RL approach results in a sequence of estimated optimal
dosing policies pi1, pi1:2, . . . with pi1:c denoting the estimated optimal dosing policy based on TDM
data y1:c, i.e. based on E1:c. In addition, we do not need to estimate the individualized action-value
function from scratch, but can exploit qpi0 := qˆpiUCT as a prior determined by the RL scheme prior to any
TDM data (see paragraph following Eq. (14)). In PUCT (predictor+UCT [27, 42]), the exploitation
vs. exploration parameter c in Eq. (14) is modified to prioritize doses with high a-priori expected
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long-term return:
Uk(sc, d) = q
1:c
k (sc, d)︸ ︷︷ ︸
exploitation
+ c ·
exp
(
qˆpiUCT (s, d)
)∑
d′ exp
(
qˆpiUCT (s, d
′)
)︸ ︷︷ ︸
priortising
√
Nk(sc)
Nk(sc, d) + 1︸ ︷︷ ︸
exploration
. (17)
Finally, we define pi1:cPUCT = pi
1:c
K based on E1:c as an estimate of the optimal individualized dosing
policy in the training setting (using Eqs. (13)+(17)), and qˆpicPUCT = qK as an estimate of the associated
expected long term return based on E1:c. For individualized dose recommendations in a clinical TDM
setting, we again use pi∗ = arg max qˆpi1:cPUCT , i.e., c = 0 in Eq. (17). See Figure 3 and 4, and Section S 7.
Algorithm 1 DA-RL guided dosing
Sample particles to get ensemble E0 from the prior pΘ
( · ; θTV(cov),Ω)
Get s0 based on covariates and baseline measurement
Choose optimal dose d∗1 = arg max
d∈D
qˆpiUCT(s0, d)
for c = 1 : C do
E1:c ← update ensemble E1:c−1 by assimilating data yc (DA part)
sc ← posterior expectation under ensemble E1:c
qˆpi1:cPUCT ← MCTS with PUCT using the ensemble E1:c
Choose optimal dose d∗c+1 = arg max
d∈D
qˆpi1:cPUCT(sc, d)
end for
Figure 4: Pseudo Code of DA-RL-guided dosing. At therapy start a particle ensemble E0 for the
sequential data assimilation (DA) approach is sampled from the prior parameter distribution given the
patient’s covariates. Then for the initial state s0 (pretreatment) the first dose is selected according
to the prior expected long-term return qpi0 := qˆpiUCT calculated beforehand in the prior planning
phase (Monte Carlo Tree Search (MCTS) with upper confidence bound applied to trees (UCT)).
The selected dose is given to the patient and patient-specific therapeutic drug/biomarker monitoring
(TDM) data yc is collected within cycle c. The TDM data is assimilated via a sequential DA approach
(particle filter and smoother) creating a posterior particle ensemble E1:c. For subsequent dose decisions
(c = 1, . . . , C). The new patient state is inferred using E1:c, e.g., smoothed posterior expectation of
the nadir concentration translated into the neutropenia grade of the cycle. Then a MCTS is started
from the current patient state using E1:c in the model simulations. Within the tree search we use the
PUCT algorithm with prioritized exploration based on qˆpiUCT .
3 RESULTS
3.1 Novel individualized dosing strategies decreased the occurrence of
grade 4 and grade 0 neutropenia compared to existing approaches
We compared our proposed approaches with existing approaches for MIPD based on simulated TDM
data in paclitaxel-based chemotherapy. The design was chosen to correspond to the CEPAC-TDM
study [14]: neutrophil counts at day 0 and 15 of each cycle were simulated for virtual patients employ-
ing a PK/PD model for paclitaxel-induced cumulative neutropenia (Figure S 1) [29]. We focused only
on paclitaxel dosing; we did not take into account drop-outs, dose reductions due to non-haematological
toxicities, adherence and comedication. Occurrence of grade 4 neutropenia, therefore, differed between
our simplified simulation study and the clinical study (as might be expected), see Section S 8.2.
This should be taken into account when interpreting the results. To obtain meaningful statistics, all
analyses were repeated N = 1000 times with covariates sampled from the observed covariate ranges in
the CEPAC-TDM study. Detailed discussions and further analyses are provided in Section S 2 and S 8.
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Figure 5 shows the predicted neutrophil concentrations—median & 90% confidence interval (CI)—
over six cycles of three weeks each. A successful neutrophil-guided dosing should result in nadir
concentrations within the target range (grades 1-3, between black horizontal lines). In all cycles, PK-
guided dosing prevented the nadir concentrations (90% CI) to drop as low as for the standard dosing
(Figure 5 A). However, PK-guided dosing also increased the occurrence of grade 0 (Figure 6).
RL-guided dosing controlled the neutrophil concentration well across the cycles (Figure 5 B) and
the distribution of nadir concentrations over the whole population was increasingly concentrated within
the target range (panel F). The occurrence of grade 0 and 4 neutropenia was substantially reduced
compared to standard and PK-guided dosing (Figure 6).
For MAP-guided dosing, the occurrence of grade 4 neutropenia increased over the cycles (Figure 6),
showing the typical cumulative trend of neutropenia [29], despite inclusion of TDM data. In contrast,
DA steadily guided nadir concentrations into the target range (Figure 5 D and F), thereby substantially
decreasing the variance, i.e., the variability in outcome. The occurrence of grade 0 and 4 was reduced
considerably in later cycles (Figure 6), suggesting that individualized uncertainty quantification played
a crucial role in reducing the variability in outcome.
Integrating individualized uncertainties and considering the model state of the patient in the RL
approach (DA-RL-guided dosing) also moved nadir concentrations into the target range and clearly
decreased the variance (Figure 5 B+F). The slight differences between DA and DA-RL (Figure 6) might
be related to the difference in weighting grade 0 and 4 in the respective reward functions (eq. (16) vs.
eq. (7)). For additional comparisons, see Figure S 22.
In summary, individualized uncertainties as in DA- and DA-RL-guided dosing seemed to be crucial
in bringing nadir concentrations into the target range and reducing the variability of the outcome, thus
achieving the goal of therapy individualization. For this specific example, both approaches showed
comparable results, but DA-RL has the greater potential for long-term optimization in a delayed
feedback environment as well as integrating multiple endpoints.
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A PK-guided dosing B RL-guided dosing
C MAP-guided dosing D DA-guided dosing
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DA-guided dosing
RL-guided dosing
DA-RL-guided dosing
90 % CI median target range nadir conc. (g=1, 2, 3)
de
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nadir conc [109 cells/L]
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1Figure 5: Comparison of different dosing policies for paclitaxel dosing. Comparison of the
90 % confidence intervals and median of the neutrophil concentration for the test virtual population
(N = 1000) using (A) PK-guided dosing (B) RL-guided dosing (C) MAP-guided dosing, (D) DA-
guided dosing, and (E) DA-RL-guided dosing, each in comparison to the standard dosing (BSA-
based dosing). PK-guided dosing is the only approach that also takes into account exposure data
(TCdrug≥0.05µmol/L). (F) Comparison of the distributions of model-predicted nadir concentrations
(smooth by kernel density estimation) for the test virtual population (N = 1000).
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Figure 6: Occurrence of grade 0 and grade 4 for the different dosing policies. The percentage
is based on a test virtual population (N = 1000) and six cycles (inferred from the model predicted
nadir concentration). Additional analyses is provided in the supplement, Figure S 22.
3.2 Identification of relevant covariates via investigating the expected long-
term return in RL
A key object in RL is the expected long-term return or action-value function qpi(s, d) (see eq. 10).
We demonstrate that it contains important information to identify relevant covariates to individualize
dosing.
Figure 7 A shows the estimated action-value function for RL-guided dosing stratified for the co-
variates, sex, age and baseline neutrophil counts ANC0 (covariate classes are shown in the legend)
for the first cycle dose selection. ANC0 was found to be by far the most important characteristic for
the RL-based dose selection at therapy start. Differences in age and sex played only minor roles. For
comparison, the first cycle dose selection in the PK-guided algorithm is only based on sex and age. The
steepness of the curves gives an idea about the robustness of the dose selection. For the second dose
selection, the grade of neutropenia in the first cycle (g1) has the largest impact, while larger ANC0
led to larger optimal doses (Figure 7 B). To illustrate the dose selection in RL, we extracted a similar
decision tree to the one developed by Joerger et al. [13], see Figure S 13.
Similar investigations are not straightforward for MAP- or DA-guided dosing as no means is pro-
vided to investigate dose recommendations for an entire population; these approaches optimize doses
for a single patient.
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1Figure 7: Expected long-term return across the dose range for dose selection. A across the
considered covariate combinations for the dose selection in cycle 1. The symbols plotted below the
x-axis show the optimal dose for the corresponding covariate class (i.e. the arg max of the plotted
line). B for fixed sex and age class (here, male between 50 and 60 years) with different pre-treatment
neutrophil values ANC0 and observed neutropenia grades in cycle 1, i.e., g1. The optimal dose for the
second cycle depends on the neutropenia grade of the previous cycle and the pre-treatment neutrophil
count ANC0 in [10
9cells/L]. The grey dashed line shows the maximum and minimum possible return
from the first cycle (A) and the second cycle (B) onwards, with γ = 0.5. The covariate classes were
chosen based on the CEPAC-TDM study population: inclusion criteria were ANC0 > ·1.5 · 109cells/L;
the typical baseline count for male was ANC0 = 6.48 · 1.5 · 109cells/L (arm B). The median age was 63
years ranging from 51 to 74 years (5th and 95th percentile of the population in arm B), see [38, 14].
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4 DISCUSSION
We present three promising MIPD approaches employing DA and/or RL that substantially reduced
the number of (virtual) patients in life-threatening grade 4 and grade 0, a surrogate marker for efficacy
of the anticancer treatment.
RL-guided dosing in oncology has been proposed before [25], however, only considering the mean
tumor diameter. Since only a marker for efficacy was considered this led to a one-sided dosing scheme
and resulted in very high optimal doses. The authors therefore introduced action-derived rewards, i.e.,
penalties on high doses. In contrast, neutrophil-guided dosing considers toxicity and efficacy (link to
median survival) simultaneously. Ideally, dosing decisions should also include other adverse effects,
e.g., peripheral neuropathy, tumor response or long-term outcomes, e.g., overall or progression free
survival. Notably, RL easily extends to multiple adverse/beneficial effects and is especially suited for
time-delayed feedback environments [23, 34], as typical in many diseases.
Using MCTS with UCT, we employed an RL framework that exploits the possibility to simulate
until the end of therapy and evaluate the return. Consequently, it requires less approximations as
temporal difference approaches (e.g., Q-learning, used in [25]) that avoid computation of the return
via a decomposition (Bellman equation). Moreover, exploration via UCT allows to systematically
sample from the dose range (as opposed to an -greedy strategy) and allows to include additional
information, e.g., uncertainties or prior information (as in PUCT). This becomes key when combined
with direct RL based on real-world patient data, see e.g. [43, 44], which would allow to compensate
for a potential model bias. At the end of a patient’s therapy the observed return can be evaluated
and used to update the expected return qˆpi. This update would even be possible if the physician did
not follow the dose recommendation (off-policy learning) and could be implemented across clinics, as
it could be done locally without exchanging patient data. Thus, the presented approach builds a basis
for continuous learning post-approval, which has the potential to substantially improve patient care,
including patient subgroups underrepresented in clinical studies.
Overall we have shown that DA and RL techniques can be seamlessly integrated and combined
with existing NLME and data analysis frameworks for a more holistic approach to MIPD. Our study
demonstrates that incorporation of individualized uncertainties (as in DA) is favorable over state-
of-the-art online algorithms such as MAP-guided dosing. The integrated DA-RL framework allows
not only to consider prior knowledge from clinical studies but also to improve and individualize the
model and the dosing policy simultaneously during the course of treatment by integrating patient-
specific TDM data. Thus, the combination provides an efficient and meaningful alternative to solely
DA-guided dosing, as it allocates computational resources between online and offline and the RL
part provides an additional layer of learning to the model (in form of the expected long-term return)
that can be used to gain deeper insights into important covariates for the dose selection. Therefore
showing that RL approaches can be well interpreted in clinically relevant terms, e.g., highlighting the
role of ANC0 values. Well-informed and efficient MIPD bears huge potential in drug-development as
well as in clinical practice as it could (i) increase response rates in clinical studies [1], (ii) facilitate
recruitment by relaxing exclusion criteria [3], (iii) enable continuous learning post-approval and thus
improve treatment outcomes in the long-term.
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1 Introduction
In this supplementary text we provide more details about the employed methods, implemented algorithms and
applied models. We also recap some general concepts in RL to support the reading of the manuscript and discuss
tuning and robustness aspects. In combination with the main manuscript, it should be self-contained and together
with the MATLAB code provided, it should enable reproduction of the simulation studies and implementation of
the methods for own applications.
Abbreviations
ANC Absolute neutrophil counts
BSA Body surface area
CEPAC-TDM Central European Society for Anticancer Research (CESAR)
Study of Paclitaxel Therapeutic Drug Monitoring
DA Data assimilation
IIV Inter-individual variability
IOV Inter-occasion variability
MAP Maximum a-posteriori
MCTS Monte Carlo Tree Search
MIDT Model-informed dosing table
MIPD Model-informed precision dosing
NLME Nonlinear mixed effects analysis
PK Pharmacokinetics
PD Pharmacodynamics
PUCT Predictor + UCT
RL Reinforcement learning
RUV Residual unexplained variability
TDM Therapeutic drug/biomarker monitoring
TV Typical values
UCT Upper confidence bound applied to trees
Table S 1: Abbreviations used throughout the manuscript and supplement.
2 Pharmacokinetic/pharmacodynamic (PK/PD) model for paclitaxel-
induced cumulative neutropenia
We have employed published models describing the pharmacokinetics of paclitaxel as well as one of its side effects
on the hematopoietic system. The simulation framework was previously described in the supplementary material
of [1].
2.1 Paclitaxel PK model
Paclitaxel is a widely used anticancer drug in the treatment of ovarian, mammary and lung cancer [2–4]. In this
study, we investigated its use as first-line treatment against advanced non-small cell lung cancer in platinum-based
combination therapy [5, 6]. Paclitaxel pharmacokinetics were previously described by a three compartment model
with nonlinear distribution to one of the peripheral compartment and nonlinear elimination [7]. For our analysis
we used the re-estimated parameter values in [8], see also Table S 2. The PK model includes a covariate model on
the maximum elimination capacity
VMEL,TV,i = VMEL,pop ·
( BSAi
1.8m2
)θVMEL-BSA · (θVMEL-SEX)SEXi · (AGEi56y )θVMEL-AGE · (BILIi7µM )θVMEL-BILI ,
where BSA denotes the body surface area of individual i, SEX the patient’s gender (0/1 for female/male), AGE
the patient’s age (in years) and BILI the bilirubin concentration. In addition to inter-individual variability and
residual variability, interoccasion variability was included on two parameters, VMEL as well as the central volume
of distribution V1. An occasion was defined as the start of a chemotherapeutic cycle c,
θi,c = θ
TV
i (cov) · eηi+κi,c , ηi iid∼ N (0,Ω), κi,c iid∼ N (0,Π) .
3
structural submodel
V1 10.8 [L]
V3 301 [L]
KMEL 0.667 [µM]
VMEL,pop 35.9 [µmol/h]
KMTR 1.44 [µM]
VMTR 175 [µmol/h]
k21 1.12 [1/h]
Q 16.8 [1/h]
covariate submodel
θVMEL-BSA 1.14
θVMEL-SEX 1.07
θVMEL-AGE -0.447
θVMEL-BILI -0.0942
statistical submodel IIV
ω2V3 0.1639
ω2VMEL 0.0253
ω2KMTR 0.3885
ω2VMTR 0.077
ω2k21 0.008
ω2Q 0.1660
statistical submodel IOV
pi2V1 0.1391
pi2VMEL 0.0231
statistical submodel RV
σ2 0.0317
Table S 2: Pharmacokinetic parameter estimates of the previously published PK model [7] for the anticancer drug
paclitaxel (re-estimated by [8]).
The system of ordinary differential equations (odes) describing rate of change of the amount in [µmol] of paclitaxel
is given by
dCent
dt
= u(t)− VMEL · C1
KMEL + C1
+ k21Per1− VMTR · C1
KMTR + C1
+ k31Per2− k13Cent , Cent(0) = 0
dPer1
dt
=
VMTR · C1
KMTR + C1
− k21Per1 , Per1(0) = 0
dPer2
dt
= k13Cent− k31Per2 , Per2(0) = 0
where Cent refers to the central compartment, and Per1, Per2 to the first and second peripheral compartment,
respectively, and C1(t) = Cent/V1 denotes the concentration in plasma, k13 = Q/V1 and k31 = Q/V3, where V3
denotes the volume of Per2, u(t) is the dosing input, see also Figure S 1 (left part) for a schematic representation
of the model.
2.2 Bone Marrow Exhaustion model (PD model)
In the CEPAC-TDM study [6] cumulative neutropenia was observed, i.e., the lowest neutrophil concentration (nadir)
as well as the maximum neutrophil concentration decreased over the course of treatment. A potential hypothesis
for this cumulative behavior is that the drug also affects the long-term recovery of the bone marrow (bone marrow
exhaustion). The gold-standard model for neutropenia by Friberg et al. [9] does not describe this long-term effect
and was shown to overpredict neutrophil concentration at later cycles [4, section 3.3]. Therefore, Henrich et al. [8]
extended the model to include a stem cell compartment, representing pluripotent stem cells with slower proliferation,
which are also affected by the drug, see Figure S 1.
The proliferation rates for the two compartments Prol and Stem are given by
kprol = ftr · ktr
kstem = (1− ftr) · ktr ,
respectively, where ktr = 4/MTT denotes the transition rate constant of the maturation chain and ftr the fraction
of input in Prol via replication. The baseline neutrophil count Circ0 =ANC0 was inferred from the baseline data
point y0 (baseline method 2 in [10])
Circ0,i = y0 · eσ·ηCirc0,i , ηCirc0,i ∼ N (0, 1) .
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Figure S 1: PK/PD model scheme for paclitaxel-induced neutropenia. The mathematical model includes a
PK model describing the pharmacokinetics of paclitaxel [7] as well as a PD model describing the cytotoxic effect of
the drug on the hematopoietic system [8]. The proliferation rate of the stem cells kstem as well as of the proliferating
cells kprol is affected by the drug. The observable is the concentration of neutrophils in the systemic circulation
Circ (blue circle). From the lowest neutrophil concentration (nadir) the grade of neutropenia is inferred.
Structural submodel
Circ0 baseline method [10
9cells/L]
MTT 145 [h]
Slope 13.1 [1/µM]
γ 0.257
ftr 0.787
Statistical submodel
ω2Slope 0.2007
σ2 0.2652
Table S 3: Parameter estimates for the bone marrow exhaustion model and the anticancer drug paclitaxel, taken
from [8].
The system of odes describing the structural model reads
dStem
dt
= kstemStem · (1− Edrug) ·
(Circ0
Circ
)γ
− kstemStem , Stem(0) = Circ0
dProl
dt
= kprolProl · (1− Edrug) ·
(Circ0
Circ
)γ
+ kstemStem− ktrProl , Prol(0) = Circ0
dTransit1
dt
= ktrProl− ktrTransit1 , Transit1(0) = Circ0
dTransit2
dt
= ktrTransit1− ktrTransit2 , Transit2(0) = Circ0
dTransit3
dt
= ktrTransit2− ktrTransit3 , Transit3(0) = Circ0
dCirc
dt
= ktrTransit3− kcircCirc , Circ(0) = Circ0
where kcirc = ktr and Edrug = Slope · C1 the linear drug effect. Note that the model implicitly assumes that the
volumes of all compartments are identical. Henrich et al. [8] calibrated this model in a population analysis to the
CEPAC-TDM study data [6].
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3 PK-guided dosing
In order to put our proposed approaches into context, we compared the results with previously applied dosing
algorithms. For the sake of completeness, we repeat here the algorithm developed and applied by Joerger et al. [6,7]
(called PK-guided dosing) as we used it for comparison throughout the manuscript. In the PK-guided dosing, the
dose of the first cycle is determined based on age and sex. For subsequent cycles the dose is adjusted according
to exposure (time during which the drug concentration is above 0.05µM) and neutropenia grade observed in the
previous cycle (inferred from observation at day 15). Thus, the algorithm is not completely offline, since the
exposure measure is inferred online using the PK model. The PD-based adaptations, which were the focus in this
study, however, were performed offline.
cy
cl
e
1
Patient age Paclitaxel dose in Paclitaxel dose in
[y] women [mg/m2] men [mg/m2]
< 46 185 200
46− 50 180 195
51− 55 175 190
56− 60 170 185
61− 65 160 175
> 65 150 165
cy
cl
e
2+
TC>0.05 Dose
[h] adjustment
> 50 −40%
41− 50 −30%
31− 40.9 −25%
< 31 −20%
TC>0.05 Dose
[h] adjustment
> 50 −30%
41− 50 −25%
31− 40.9 −20%
< 31 ±0%
TC>0.05 Dose
[h] adjustment
> 50 −30%
41− 50 −25%
31− 40.9 −20%
26− 30.9 ±0%
20− 25.9 +10%
10− 19.9 +20%
< 10 +30%
prev
ious
cyc
le g
= 4
previous cycle g = 0− 2
previous cycle g = 3
1
Figure S 2: Diagram of the PK-guided dosing algorithm adopted from [7].
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4 MAP-guided dosing
MAP-guided dosing is widely applied in various therapeutic areas for online therapy individualization [11, 12] and
implemented in assorted software tools, e.g. TDMx [13], InsightRX [14]. The optimal dose is determined in a
two-step procedure:
1. The MAP-estimate θˆMAP1:c is computed by minimizing the negative log-posterior over the observed data points
θˆMAP1:c = arg min
θ
−log p(θ|y1:c) ,
where y1:c denotes the patient-specific TDM data collected up to the end of cycle c. The posterior is pro-
portional to the likelihood times the prior, i.e., p(θ|y1:c) ∝ p(y1:c|θ) · p(θ). Often, the prior p(θ) is chosen to
be lognormal and the likelihood is chosen to be gaussian for log-transferred data (additive error model on
log-scale). The method is outlined in more detail in [1, 15].
2. Then, the MAP estimate is used to generate model predictions for solving the objective problem in the dose
selection at start of cycle c+ 1
d∗c+1 = arg min
d
−R(cnadir(θˆMAP1:c , d)),
where we investigated different evaluation functions R(·) based on the MAP-based nadir concentration, see
Section S 8.5. Typically, a utility function is maximized or the deviation to a target concentration is minimized.
MAP-guided dosing depends largely on the reliability of MAP-based predictions which, however, do not neces-
sarily represent the most probable therapeutic outcomes and neglect model uncertainties [1]. In particular, any
distributional information like, e.g., the tails of the posterior distribution which describe sub-therapeutic as well
as toxic ranges, are completely neglected. These tails provide crucial information for dose selection and might be
pronounced due to the often chosen lognormal prior parameter distributions. In addition, the choice of the target
or utility function has a crucial impact on the optimal dose selection. While the concept of an utility would be
quite desirable, the definition is rather challenging since clinically rather therapeutic ranges are observed.
5 DA-guided dosing
DA-guided dosing is based on Bayesian forecasting of the therapeutic outcome using sequential Bayesian DA ap-
proaches [1]. There exist many sequential but also variational DA algorithms which could be used, see e.g., [16–18].
We employed in the simulation studies a basic particle filtering and smoothing algorithm [19–21] with resampling
and rejuvenation (M = 100). Particle filters are well suited to the setting in pharmacometrics with nonlinear
models and non-gaussian prior distributions as they do not make an assumption on the distribution of the posterior
and provide a correct estimation of the posterior in the limit of large sample sizes (M → ∞, without rejuvena-
tion) [17,19,22]. We considered the setting of an augmented state space, adding the model parameters to the model
states to simultaneously update the states and parameters sequentially. Smoothing was realised via resampling or
reweighting of the state history. The used DA approach is outlined in all detail in [1].
At decision time points Tc the current posterior ensemble is used to predict the therapy outcome under posterior
uncertainty. Thus, the probabilities of subtherapeutic/toxic outcomes can be computed and integrated in the
optimal dose selection allowing to simultaneously integrate efficacy and safety aspects into the dose selection. Note
that the dose finding problem is a multi-objective optimization problem, and that it is not possible to simultaneously
decrease the probability of grade 4 and the probability of grade 0.
7
Common notation
pi generic policy
qpi expected return given generic policy pi
Notation specific to MCTS+UCT
pik policy in training phase
qk sample approximation of qˆpik in training phase
pˆiUCT := piK policy after training phase (incl. exploration)
qˆpiUCT := qK sample approx at the end of training phase
pi∗ = arg max qˆpiUCT RL-guided dosing policy (clinical setting, no exploration)
Notation specific to MCTS+PUCT
qpi0 := qˆpiUCT prior estimated return
pi1:ck policy in training phase using ensemble E1:c
q1:ck sample approximation in training phase using ensemble E1:c
pˆi1:cPUCT := pi
1:c
K policy after training phase using ensemble E1:c (incl. exploration)
qˆpi1:cPUCT := q
1:c
K sample approx at the end of training phase using ensemble E1:c
pi∗ = arg max qˆpi1:cPUCT DA-RL-guided dosing policy (clinical setting, no exploration)
Table S 4: Notation related to the reinforcement learning approaches used in RL-guided and DA-RL-guided dosing.
6 RL-guided dosing
There exist many different RL algorithms for computing the action-value function [23–25]. We have restricted our
analysis to two popular and powerful methods with relevance in clinical decision-making: Monte Carlo tree search
is a popular choice for episodic tasks (finite time horizon) [26], and Q-learning [27] for continuous and episodic tasks
(infinite time horizon). As both types of tasks—episodic and continuous—are of relevance in dosing policies we
considered both here. Due to our specific application setting (episodic task of six treatment cycles), however, our
focus is on MCTS.
6.1 Monte Carlo tree search (MCTS) with UCT
Monte Carlo tree search combines the Monte Carlo method with tree search. It was mainly developed and applied
to game-tree search, e.g., AlphaGo [28]. To efficiently explore the search tree (Figure 2) we used as tree policy the
upper confidence bound applied to trees (UCT) [26, 29]. MCTS comprises four recursive steps which are repeated
in each episode k = 1, . . . ,K for building a search tree based on random samples in the decision space [30] (see
Figure S 3):
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1Figure S 3: Illustration of Monte Carlo tree search (MCTS). 1.) Selection: within the search tree, actions
are selected according to the tree policy, until a not yet fully expanded node is reached. 2.) Expansion: The action
is chosen among the unvisited actions according to a roll-out policy (e.g., random) and the new node is added to the
search tree. 3.) Simulation: From the new child node, a simulation is started using the roll-out policy until the end
of the episode/therapy. 4.) Back-propagation: The return is back-propagated through the tree, i.e., action-values
functions and number of visits are updated for each selected state-action pair within the search tree.
• Selection: Starting at the root node s0 actions are selected according to the tree policy (pik) until a not yet
fully expanded node, i.e., a node with an unvisited action, is reached.
• Expansion: If the selected node is expandable (nonterminal state), one child node is added by selecting an
unvisited action.
• Simulation: Following a default policy (often random) a single simulation is run until a terminal state is
reached. The return of this episode is calculated.
• Backpropagation: The simulated return is backpropagated to the selected nodes in the search tree. More
specifically, back up means we compute incrementally the expected return (qk) via a running mean, i.e., in
episode k
qk(sc, d) = qk−1(sc, d) +
1
Nk(sc, d)
(
G(k)c − qk−1(sc, d)
)
.
Note that we consider a basic version of MCTS and various modifications are possible, e.g., adding several child
nodes in the expansion step or running multiple simulations in parallel. More details about the implementation and
chosen tuning parameters are provided in Section S 8.7. In brief, in our setting for each episode k, a virtual patient is
generated with covariates cov(k) in the corresponding covariate class, say COV l, sampled according to the obsefved
covariate distributions of the CEPAC-TDM study, and the individual model parameters θ(k) ∼ pΘ
(
θTV(cov(k)),Ω
)
are sampled from the corresponding prior parameter distributions.
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The UCT algorithm is based on Hoeffding’s inequality [31]. We consider the setting of [31, Theorem 2]: Let
X1, . . . , Xn be independent, bounded random variables, i.e., ai ≤ Xi ≤ bi with sample mean X¯ = (X1 + . . .+Xn)/n,
then
P
[
E[X] > X¯ + u
] ≤ exp( −2n2u2∑n
i=1(bi − ai)2
)
. (S 1)
Translating this into the RL setting for X = G [29, 32]
P [qpi(s, d) > qk(s, d) + Uk(s, d)] ≤ exp
(
−2Nk(s, d)
2Uk(s, d)
2∑
i(bi − ai)2
)
, (S 2)
Choose probability α that the true value exceeds the upper bound
exp
(
−2Nk(s, d)
2Uk(s, d)
2∑
i(bi − ai)2
)
= α (S 3)
leads to the upper bound
Uk(s, d) =
√
(b− a)2 ·
√
− logα
2Nk(s, d)
, (S 4)
with b = bi and a = ai for all i = 1, . . . , Nk(s, d), i.e., the maximum and minimum return does not change. In the
bandit literature, it was shown that α = Nk(s)
−4 ensures logarithmic regret [29], where Nk(s) :=
∑
d′ Nk(s, d
′) the
number of visits of state s and leads to the UCB1 algorithm for the case [ai, bi] = [0, 1] for i = 1, . . . , n [29] with
upper bound
Uk(s, d) =
√
2 logNk(s)
Nk(s, d)
. (S 5)
In [32] the bound
Uk(s, d) =
√
Nk(s)
1 +Nk(s, d)
(S 6)
was used, which corresponds to
α = exp
(
−2Nk(s, d) · Nk(s)
1 +Nk(s, d)
)
≈ exp (−2Nk(s))
for the bounds [0, 1]. Note, the adding 1 in the denominator of Eq. (S 6) avoids division by zero, i.e., if the dose
has not been taken before. The UCB1 Algorithm is actually initialized by taking each action once; this is, however,
not possible in our tree setting. The bound in Eq. (S 6) encourages exploration as the numerator is larger than in
Eq. (S 5). As we are in a pure model-based learning setting, we want to encourage exploration as we do not have
to pay a price for a suboptimal outcome, i.e., we are not interested in maximizing the cumulative reward but in
learning an optimal policy. Therefore, we considered (in our learning setting) the bound
Uk(s, d) =
√
(b− a)2 ·
√
Nk(s)
1 +Nk(s, d)
, (S 7)
where the first factor is included in the exploration-exploitation parameter , see also Eq. (S 10). When model-based
learning is completed and one would aim at continued learning from real patients one should rather choose a more
cautious exploration strategy as in (S 5).
6.2 Q-learning
As we considered an episodic task of six treatment cycles, we employed MCTS. For long-term therapy plans,
however, temporal difference approaches based on a one step look-ahead approach could be beneficial as they do
not require the computation of the total return (requiring simulation until the terminal state). The choice of
algorithm is therefore problem dependent. Q-learning is based on the decomposition of the action-value function
into an immediate reward and adiscounted action-value of successor state and action (Bellman)
qpi(s, d) = Epi[Rc+1 + γqpi(Sc+1, Dc+1)|Sc = s,Dc = d] .
In Q-learning the action-value function is also learned iteratively
qk+1(sc, d)← qk(sc, d) + α ·
(
Rc+1 + γ ·max
d′
[qk(sc+1, d
′)]− qk(sc, d)
)
, (S 8)
where sc+1 is the next state when giving dose d in state sc. Parameters which need to be specified are
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• learning rate α
• exploitation and exploration parameter 
To ensure convergence, the learning rate needs to decay appropriately with the number of iterations, e.g., as a
Robbins-Monro sequences [33]. Similarly as in MCTS, the learner is confronted with a trade-off between exploration
and exploitation. In Q-learning, frequently the -greedy approach is used: With probability , a random action is
chosen and with probability 1− , the greedy action, i.e., the current argmax of qpi, is chosen. Also  can be chosen
in a decreasing manner, to encourage exploration in the beginning and exploitation at later training episodes.
7 Combining DA and RL: DA-RL-guided dosing
DA can be integrated into RL in two ways, (i) by improving the state representation, and (ii) by using the posterior
ensemble in a decision-time planning procedure to update and individualize the estimate of the qpi-values reflecting
the posterior uncertainty.
First, before any patient is treated, a prior dosing policy qˆpiUCT is planned, i.e., determined, via model-based RL,
e.g., via MCTS+UCT as in Section S 6.1.
When a patient is to be treated, the ensemble E0 for the sequential DA algorithm, e.g., particle filter/smoother, is
initialized. The patient-specific TDM data y1:c is integrated, leading to an updated posterior particle ensemble E1:c.
At a decision time point Tc, the posterior expectation is computed for an improved estimate of the current patient
state, e.g., a sample approximation to the posterior expectation of a nadir concentration
cˆnadir =
M∑
m=1
w(m)c · cnadir
(
x
(m)
1:c , θ
(m)
)
,
where cnadir(x
(m)
1:c , θ
(m)) denotes the minimum neutrophil concentration of the m-th particle within the cycle. The
posterior expected nadir cˆnadir is translated to the corresponding neutropenia grade of the cycle gc and used to
update the current patient state sc. A MCTS search tree is initialized at the current patient state sc and the search
within the tree is guided by the PUCT algorithm [32], where prior probabilities of choosing a dose are computed
from the prior qˆpiUCT -values, see Eq. (17). For model simulations within each episode in the MCTS the model state
parameter vector x(k) and θ(k) is sampled from the posterior particle ensemble E1:c.
8 Simulation study: neutrophil guided dosing of paclitaxel over mul-
tiple cycles
8.1 Setting
The simulation study was performed in MATLAB R2017b/2018b using the previously described PK/PD model [8].
In the offline approaches, the second neutrophil measurement (at day 15 of the cycle) is used to infer the grade
of neutropenia (according to the common terminology criteria for adverse events [34], see also Figure 3). The
generated virtual patient populations for training and testing were sampled based on the reported covariate ranges
in the CEPAC-TDM study [6]. For the standard dosing approach, we employed the rules applied in the CEPAC-
TDM study arm A, i.e., 200 mg/m2 BSA and a 20 % dose reduction if grade 4 neutropenia was observed [6]. Note
that in clinical practice, the dose was also reduced if other severe adverse effects were observed, which was not
included in our simulation setting. To save computational time, we only optimized over the next cycle (rather than
over all remaining cycles) in the MAP-guided and DA-guided dosing. In MAP-guided dosing the sensitivities for
gradients used in the MATLAB solver fmincon were computed using the Toolbox AMICI [35,36] which requires a
MATLAB version < R2018. In RL-guided dosing we employed MCTS to exploit the characteristics of an episodic
task (six treatment cycles) instead of Q-learning.
8.2 Comparison with reported CEPAC-TDM study outcomes
In our simulation study, we followed the design of the CEPAC-TDM study. To put the simulation results into
perspective, we compared the simulated occurrence of grade 4 neutropenia (based on simulated observations on
day 15 including residual variability) with the observed occurrence in the CEPAC-TDM study for the standard
dosing (arm A) and the PK-guided dosing algorithm (arm B), see Figure S 4. We observed that we overpredict
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the occurrence of grade 4 neutropenia for standard dosing (left panel). This was attributed to the fact that the
standard dosing in arm A, the dose was also decreased if non-haematological toxicities occurred (see also comment
at the end of Section 8.1). Since our model did only allow to simulate neutropenia we could not take further aspects
into account. For the PK-guided dosing algorithm (right panel), the simulation results were well aligned with the
observed results in the CEPAC-TDM study. The occurrence of grade 4 neutropenia was comparable across all
cycles. Additional characteristics of the clinical study that we did not take into account in our simulation study
are drop-outs, adherence to the dosing instructions (e.g. the given relative dose in the first cycle in study arm A
ranged from 150 mg/m2 to 215 mg/m2) and comedication (e.g. therapeutic GCSF).
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Figure S 4: Comparison of predicted grade 4 neutropenia with observed occurrence in the CEPAC-
TDM study. Blue bars show the results from the simulation study (based on day 15 observation) and white bars
show the results from the CEPAC-TDM study. Clearly, the occurrence of grade 4 is overestimated for the standard
dosing in the simulation study, but comparable for the PK-guided dosing. The results for the CEPAC-TDM study
were retrieved from [4].
8.3 Observation time points
Observation time points of neutrophil concentrations were chosen in accordance with the CEPAC-TDM study [6]:
day of the dose administration as well as day 15 of each cycle. However, in the evaluation of the dosing algorithm
the average model predicted nadir time (based on the Friberg model) was found to be on day 11.5 [7]. Therefore,
we investigated also day 12 als alternative sampling time point.
In Figure S 5, we examined the correlation between the model predicted nadir (based on the BME model) and the
simulated neutrophil concentration at day 12 and 15. For larger nadir concentrations (nadir > 1 · 109cells/L) the
neutrophil concentrations at day 15 clearly overpredict the true nadir, i.e., underpredicts the severity of neutropenia.
For small nadir concentrations (nadir ≤ 1 · 109cells/L) the correlation between model predicted nadir and model
predicted neutrophil concentration at day 15 seems to be better. This information could be relevant for future
studies and demonstrates the importance of optimal sampling time points and the benefit of an model-informed
analysis.
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Figure S 5: Comparison of the model predicted nadir concentration compared to the model predicted
neutrophil concentration at days 12 and 15. The standard dosing was used for simulation of the neutropenia
time-courses for 1000 virtual patients.
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Figure S 6: Comparison of different dosing policies for paclitaxel dosing based on observations at day
12. Comparison of the 90 % confidence intervals and median of the neutrophil concentration for the test virtual
population (ntest = 1000) using (A) the standard dosing and PK-guided dosing (B) MAP-guided dosing, (C) DA-
guided dosing, (D) RL-guided dosing and (E) DA+RL-guided dosing. (F) Occurrence of grade 0 and grade 4 across
the different dosing policies for the test population over the six cycles.
8.4 PK-guided dosing
We also compared the effect of the sampling time point on the PK-guided dosing algorithm by applying the algorithm
to the test virtual population, see Figure S 7. For this the neutropenia grade of the previous cycle was inferred
either based on simulated neutrophil measurements at day 12 or day 15 in the previous cycle (including residual
variability). The occurrence of neutropenia grade 4 (evaluated based on model predicted nadir) was slightly higher if
the previous cycle grade was inferred from the measurement at day 15 compared to day 12. Thus, the sampling time
14
point has an effect on the PK-guided dosing algorithm and a sampling time point around day 12 is advantageous.
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Figure S 7: Comparison of the results when PK-guided dosing was based on the neutrophil measure-
ment at day 12 or day 15.
8.5 MAP-guided dosing
In literature, a utility function based on a hypothetical survival probability across the different neutropenia grades
was investigated [37]. We proposed a utility function that was designed to mirror the essence of the reward function
which we employed in RL-guided dosing to enable a fair comparison, see Figure S 8. In order to also offer a
comparison to the often used concept of a target concentration, we also performed target concentration intervention
with a target of cnadir = 1 · 109cells/L [12]. For this, we minimized the squared difference, i.e., R(sc) = (sc − 1)2,
where the model state of the patient state was given by
sc = min
t∈[Tc,Tc+1]
cneutrophils
(
t; θˆMAP, d
)
. (S 9)
For the target concentration intervention, the 90% CI of the neutropenia time-courses of the virtual test population
reached lower neutrophil concentrations compared to the utility function and increased the occurrence of grade 4
neutropenia across all cycles, see Table S 5 and Figure S 8.
cycle 1 2 3 4 5 6
Utility function 10.5% 7.4% 11.4% 16.5% 21.3% 23.5%
Target deviation 22% 15.3% 22.3% 29.9% 34.6% 41.5%
Table S 5: Occurence of grade 4 neutropenia across cycles for MAP-guided dosing.
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Figure S 8: Comparison of different objective functions for MAP-guided dosing. Two different objective
functions were considered for MAP-guided dosing: (i) the least squared differences to a target concentration of
cnadir = 1 · 109cells/L, (ii) a utility function which penalizes low nadir concentration (in the range of grade 4
neutropenia) higher compared to high neutrophil concentrations (in the range of grade 0 neutropenia).
8.6 DA-guided dosing
For the DA-guided approach, we chose the optimal dose to be the dose that minimizes the a-posteriori probability
of being outside the target range, i.e., the weighted sum of the predicted risk of the patient having neutropenia
grade gc = 0 or gc = 4 in the next cycle, see Eq. (16). We illustrated the DA-guided dosing approach exemplarily
for the second cycle dose selection for a virtual patient, see Figure S 9. We solved the one-dimensional optimization
problem (16) using the fminbnd function in MATLAB R2018b (golden section search and parabolic interpolation).
Each objective function evaluation correspond to M model simulations for the corresponding cycle. Therefore, we
chose a rather small ensemble size M = 100 and only considered one cycle. Note that a larger ensemble size could
be chosen for the DA step, while subsequently solving the optimization problem only for a subset of the ensemble.
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Figure S 9: Exemplary dose selection for cycle 2 in DA-guided dosing. The optimal dose in DA-guided
dosing was defined to be the dose that minimizes the weighted sum of risk of grade 0 and grade 4, i.e., probability of
grade 0 and grade 4 neutropenia. Note for illustration purposes a larger number of particles was chosen M = 103.
For comparison we also propagated the particle ensemble for the case if the standard dose was chosen (blue).
8.7 RL-guided dosing
For the considered patient state representation sc = (sex, age,ANC0, g1:c), we obtained in total L = 32 covariate
classes COV1, . . . , COVL (2 genders × 4 age classes × 4 baseline neutrophil count classes), per covariate class we
have 19531 possible grade combinations for the 6 cycles, thus leading to a dimension of the discrete state space of
|S| = 624992. As we do not need to make a dose decision after the last cycle we can exclude the leafs of the tree
(grade of last cycle), reducing the total number of states to |S| = 124992.
The discrete dose steps of 5 mg/BSA were chosen within the range of given doses in the CEPAC-TDM study
dmin = 60 mg/m
2 BSA and dmax = 250 mg/m
2 BSA leading to |D| = 39.
We chose a discount factor for future rewards: γ = 0.5, see Section S 8.7.1. Note that this implies that the current
grade of neutropenia was higher weighted than future grades. Yet, γ is sufficiently large to factor in the impact of
the current dose choice on the grade of neutropenia in future cycles.
The exploration-exploitation parameter c was chosen cycle-varying, since the expected return changes over time
(cycles), due to the intermediate rewards. Based on Hoeffding’s inequality for random variables that can take values
in the interval [a, b] we get,
(c) = cUCT ·
√√√√C−c∑
k=1
γk−1 · (bk − ak)2 , (S 10)
with respect to our chosen reward function ak = −2 and bk = 1 for all k. We chose cUCT = 3. Note that the
maximum and minimum return is dependent on the current cycle as it is computed as the cumulative reward
from the current cycle onwards. The choice of all tuning parameters/reward function was further investigated in
Section S 8.7.1.
The training phase of MCTS is visualized in Figures S 10 and S 11.
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Figure S 10: Training stages of Monte Carlo tree search (MCTS): Approximation of qpi. The same
virtual test patient population was dosed according to the current estimate of the action-value function qK after
K episodes of the planning steps for the covariate class: female, age between 50 and 60 years, and pre-treatment
neutrophil counts ANC0 ∈ [5, 10) in [109cells/L].
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Figure S 11: Training stages of Monte Carlo tree search (MCTS). The same virtual test patient population
(as in Figure 10) was dosed according to the current estimate of the action-value function qK after K iterations of
the planning steps per covariate class.
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Figure S 12: Monte Carlo Tree Seach. A Expectation of the long-term return for exemplary states for the
covariate class: male, age ∈ [50, 60), ANC0 ∈ [2.5, 5) · 109cells/L. B Visiting counts of states in training phase for
K = 106.
The computed qˆpiUCT -Matrix can be used as a look-up table. For a certain patient state we need to determine the
corresponding row in the matrix and then select the dose corresponding to the maximal qˆpiUCT -value. This procedure
can be visualized in a diagram structure similar to the one developed by Joerger et al. [7], see Figure S 13. Since
RL allows to deal with a large amount of information regarding patient state/dose combinations, we just depict a
small subtree.
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Figure S 13: Illustration of the decision tree procedure for the dose selection. From the action-value
function values qˆpi a decision tree/look-up table can be extracted. Here shown for fixed covariates: male, age
∈ [50, 60). For example, the optimal dose for the second cycle depends on the neutropenia grade of the previous
cycle and the pre-treatment neutrophil count ANC0.
8.7.1 Investigating the effect of the tuning parameters
We investigated the choice of the discount parameter γ ∈ [0, 1]. In our setting, the long-term goal (median survival)
is already included in the immediate reward, since neutropenia grade 0 was also evaluated with −1 in the reward
function. Therefore, γ does not have such a strong impact on the results, see Figure S 14. The parameter is expected
to be more relevant if efficacy is not ’measured’ by the surrogate marker of neutropenia, but rather evaluated based
on a tumour growth model or a survival model. This would result in rewards with larger time lag since the choice
of a dose impacts tumour growth and in particular survivial only at (much) later time points.
We further examined the trade-off between exploration and exploitation. For this, we varied the constant cUCT
in eq. (S 10) in the MCTS with UCT approach. We found that for smaller cUCT values, the algorithm selected
only a small number of doses with relative high probability, see e.g., Figure S 15 for the initial dose selection. This
20
0 2 4 6 8 10 12 14 16 18
time [weeks]
10-1
100
101
n
e
u
tro
ph
ils
 [1
09
 
ce
lls
/L
]
0 2 4 6 8 10 12 14 16 18
time [weeks]
10-1
100
101
n
e
u
tro
ph
ils
 [1
09
 
ce
lls
/L
]
0 2 4 6 8 10 12 14 16 18
time [weeks]
10-1
100
101
n
e
u
tro
ph
ils
 [1
09
 
ce
lls
/L
]
γ = 0.1 γ = 0.5 γ = 1
Standard dosing
RL-guided dosing
90 % CI
median
target range nadir conc. (g=1, 2, 3)
1
Figure S 14: Choice of the discount parameter γ. The discount parameter γ ∈ [0, 1] weighs the relation
between short term and long-term goals. Since no discount is applied to the current cycle, small γ values give the
current cycle a much higher weighting compared to later cycles, i.e., prioritizing the short term return rather than
the long-term outcome. On the contrary, large γ values put more weight on the long-term goals. Note, this analysis
was done with sampling time points day 0 & 12 and a virtual test population of N = 1000.
led to an un-smooth action-value function, which is not expected in the considered scenario. Therefore, we chose
cUCT = 3, as this choice showed a balanced exploration of the dose space while still prioritizing doses with high
expected return.
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Figure S 15: Monte Carlo tree search: exploration/exploitation parameter. Expectation and variance of
the long-term return for exemplary states of the covariate class: male,age ∈ [50, 60), ANC0 ∈ [2.5, 5) (top panel)
and visiting counts of dose selections in the initial state s0, N(s0, d) in training phase for K = 10
6 (bottom panel)
for different exploration/exploitation parameter cUCT in eq. (S 10).
Finally, we investigated the effect of changes in the reward functions. For this, we exemplary changed the reward—
here corresponding to a penalization—of grade 4 neutropenia. In the first scenario, the reward of grade 4 neutropenia
was set equal to the reward of grade 0 neutropenia (Rc+1 = −1 , if gc = 4). Thus, subtherapeutic and toxic ranges
result in the same reward value. The second scenario, Rc+1 = −2 , if gc = 4 corresponds to the scenario presented
21
in the main manuscript. In the the third scenario, neutropenia grade 4 was even more strongly penalized, reflecting
the potential of exposing patients to immediate life-threatening conditions (Rc+1 = −3 , if gc = 4). As expected,
the occurrence of grade 4 decreased the stronger grade 4 neutropenia was penalized, see Figure S 16. Due to the
uncertainty, at the same time the incidence of grade 0 is increased. Thus, it is crucial to have a clear therapeutic goal
prior to defining the evaluation function. The choice of the evaluation function should be examined in comparison
with potential alternatives, as in Figure S 16 and the results should be compared with the desired therapeutic
outcome.
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Figure S 16: Comparison of RL-guided dosing results for changes in the reward function. In the three
scenarios the rewards for grades 0-3 remained the same and only the reward for grade 4 was changed. In the first
panel the reward value of grade 4 was set to -1, thus equal to the reward of grade 0. The second reward function
corresponds to the scenario presented in the main manuscript (-2) and in the last scenario a larger penalty is put
on grade 4 in comparison to grade 0, i.e., R=-3 if grade 4 was observed.
8.7.2 Q-planning
As an alternative to Monte Carlo Tree Search, Q planning can be performed to learn the action-value function. We
employed the same state representation and the same reward function as for the MCTS approach.
We also visualized the training phase for Q-planning, see Figure S 17. For this specific example and selected patient
state representation, the results using MCTS are more promising and could better reduce the incidence of grade 0
& 4 neutropenia in later cycles.
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Figure S 17: Training stages of Q-planning. The same virtual test patient population was dosed according to
the current estimate of the action-value function qK after K iterations of the planning steps per covariate class.
8.8 DA-RL-guided dosing
8.8.1 Different approaches to estimate the grade of neutropenia gˆc in cycle c
In DA-RL-guided dosing, the particle ensemble E1:c is used to estimate the patient state more reliably than just
using the observed neutrophil concentration at day 12 or 15. Figure S 18 shows the root means squared error
(RMSE) between the estimated neutropenia grade gˆc and the true grade gc from the underlying “truth” used to
simulate the data. Note, that we neglected the ‘ˆ’ in the main manuscript for ease of notation. Overall, the
RMSE is lower for day 12 than for day 15. Moreover, using a model-based state representation reduced the RMSE
substantially—and much more than the difference between day 12 and 15. We further compared the posterior
expected nadir concentration, see Eq. (S 7), translated into discrete grades, with first computing the probabilities of
the different grades and then using the maximum a-posteriori grade, i.e., the grade with highest sum of weight. The
posterior expected nadir concentration performed slightly better and was therefore used in the main manuscript for
approximating the patient state using the particle ensemble E1:c.
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Figure S 18: RMSE of estimating the grade of neutropenia gˆc in cycle c using different approaches.
In RL-guided dosing, the neutrophil measurement is used to infer the neutropenia grade. We investigated the two
sampling time points day 12 (typical nadir time) and day 15 (as in the CEPAC-TMD study). For DA-RL-guided
dosing, the particle ensemble E1:c can be used to infer an improved patient state. There are two options: (i) the
posterior expected nadir concentration is computed and then translated into a discrete grade; or (ii) the probability
of each grade is determined by summing the weights of particle giving raise to that grade; then, the maximum
a-posteriori grade is defined as the grade with highest sum of weights.
8.8.2 RL-guided dosing based on DA state
In the main manuscript, we discussed that DA can be used in two ways to improve RL-guided dosing: (i) providing
an improved state estimate (as in the previous section); and (ii) by using the posterior particle ensemble E1:c to
update the qˆpiUCT values in relevant and promising dose-state-pairs. In Figure S 19, we investigate the scenario (i)
alone, i.e., if we only use the improved state estimate in RL-guided dosing (without decision time planning based
on the posterior particle ensemble). We observed a one-sided improvement, only the occurrence of grade 0 was
reduced compared to RL alone. This indicates again the key role of individualized uncertainties for MIPD. In short:
if the quality of estimating the grade of neutropenia is improved, also the corresponding dosing table should be
updated,since the RL dosing table accounted for the potential “bias” in the state estimation. If not, improved
estimates are used in decision trees that have been determined based on the less accurate estimated of the grade of
neutropenia. Such a mismatch should be avoided.
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Figure S 19: RL-guided dosing based on the DA-based model state of the patient. The virtual test
population was dosed with RL-guided dosing adding the different aspects of DA. Lower left panel: RL-guided
dosing using the improved DA-based model state of the patient. Here we used the smoothed posterior expected
nadir concentration translated to the discrete neutropenia grades. Lower right panel: DA-RL-guided dosing as
presented in the main manuscript. Note, that we used the scenario with sampling time points day 0 & 12 for this
analysis.
8.8.3 PUCT algorithm
In the PUCT algorithm, the pre-calculated action-value function values qˆpiUCT have to be translated to probabilities.
As described in the main text, we used the Boltzmann distribution (see Eq. (17) in the main text) to convert the
expectation values in R to probabilities in [0, 1]. In addition, we performed a kernel density estimation to further
smooth the function in case of a rough action-value function due to small visiting counts (this step is more relevant
if less pre-training steps were possible, e.g., in larger state spaces), compare small K values (rough) to large K
values in Figure 10.
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Figure S 20: Prior probabilities for DA-RL-guided dosing. The action-value function qˆpi was translated
into probabilities P = exp(qˆpi)/Z, where Z =
∑
d exp(qˆpi(s, d)) using the Boltzmann function, and subsequently
smoothed (P smooth) using kernel density estimation. The smoothed probabilities were used in Algorithm 1 to
guide the dose selection in the individual search tree.
As a result of the updated uncertainties, the action-value function qˆpiPUCT (DA-RL-guided dosing) differ from the
static qˆpiUCT (RL-guided dosing), see Figure S 21. This also led to different optimal doses (markers at the x axis).
The purple bars show the visiting counts N of the different doses in the given state, showing that doses are chosen
more often which have high qˆpiUCT (red line) as enforced via the PUCT algorithm. It can be also seen that the
qˆpiPUCT -curve (purple line) is not very smooth in dose regions which have low qˆpiUCT values as these values are not
chosen often. In PUCT, the search focused more on promising regions of the dose space. In practical applications,
deviations from this highly focused search need to be discussed depending on how much one wants to trust the prior
knowledge or how much we expect the new patients to deviate.
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Figure S 21: Comparison of the action-value function values qˆpi and visiting counts N (normalized) for
RL-guided dosing and DA-RL-guided dosing. The individual action-value function values (DA-RL) differ
from the population values (RL). Doses are chosen more frequently in regions where the prior probabilities, defined
by the population action-value (red line), are large, see histogram (right axis). Note that it can be observed that
the qˆpi values are smoother in regions with high number of samples (e.g. cycle 2 for lower doses). Regions with low
prior probabilities (computed from RL qˆpi values(red line)) are chosen less often. Overall, this results in improved
sampling of important regions. The visiting counts were divided by the maximum number of visits for one dose
(i.e. scaled to one, N/max(N)) to allow for comparison since KRL >> KDA-RL.
8.9 Comparison across all considered evaluation functions
The different methods towards the optimal dose problem considered in the manuscript are based on different
evaluation/reward function. For a more in-depth comparison, we also show the results of the different methods with
respect to all considered evaluation functions: the utility (MAP-guided dosing), deviation from target concentration
(MAP-guided dosing), the weighted sum of occurrence of grade 0/4 (DA-guided dosing), and the total reward (RL-
guided dosing).
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Figure S 22: Comparison of methods across all evaluation functions. (A) Comparison of the utility used in
the MAP-guided dosing for all dosing strategies, see Figure S 8. The higher the utility the better (upward arrow).
(B) The deviation from a target concentration (1 · 109 · cells/L) was proposed for MAP-guided dosing (target
concentration intervention). The smaller the deviation from the target the better (downward arrow). (C) The
weighted sum of occurrence was minimized in the DA-guided approach. The occurrence of grade 4 was penalized
more strongly than the occurrence of grade 0. The smaller the weighted sum the better (downward arrow).(D)
The total reward as defined for the RL-guided dosing is to be maximized. The higher the total reward the better
(upward arrow).
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